Dipexium Pharmaceuticals to Hold Third Quarter 2015 Financial Results Conference Call on Monday, November 16, 2015, at 8:30 a.m. ET

Nov 09, 2015, 08:00 ET from Dipexium Pharmaceuticals, Inc.

NEW YORK, Nov. 9, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended September 30, 2015, on Monday, November 16, 2015 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.

To participate by telephone, please dial 877-407-8012 (U.S. & Canada) or 412-902-1013 (International) five minutes prior to the start of the call.  A live and archived audio webcast of the conference call can be accessed through the Investor Relations section of the Company's website at www.dipexiumpharmaceuticals.com under the IR Calendar tab. The archived webcast will remain available on the Company's website for 30 days following the call.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For more information, visit www.dipexiumpharmaceuticals.com.

Company Contacts:

David P. Luci President & Chief Executive Officer Dipexium Pharmaceuticals, Inc. 212-269-2834 info@dipexium.com

David Garrett Vice President, Finance & Corporate Development Dipexium Pharmaceuticals, Inc. 212-269-2834 info@dipexium.com

© 2015 Dipexium Pharmaceuticals, Inc.  All rights reserved.

SOURCE Dipexium Pharmaceuticals, Inc.